Measuring total IgE is useful in detecting exacerbations in patients with allergic bronchopulmonary aspergillosis receiving omalizumab

Use of monoclonal antibodies for allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis: literature review

“… 9 – 11 , 14 , 16 , 17 – 20 , 31 , 34 , 35 , 37 , 38 After treatment, 12 studies reported IgE, including values for 28 patients, with a median of 789 IU/mL (range 400–1950) after 5 months to 3 years of treatment. 9 – 11 , 14 , 15 , 17 , 21 , 34 , 38 Furthermore, baseline and post-treatment values were reported in 27 of 104 patients of whom 11 patients achieved a reduction greater than 35% in total IgE values (range 40–77.4% reduction) from 5 months to 3 years of treatment. 10 , 11 , 14 , 15 , 17 , 21 , 34 , 38 …”

“… 9 – 11 , 14 , 15 , 17 , 21 , 34 , 38 Furthermore, baseline and post-treatment values were reported in 27 of 104 patients of whom 11 patients achieved a reduction greater than 35% in total IgE values (range 40–77.4% reduction) from 5 months to 3 years of treatment. 10 , 11 , 14 , 15 , 17 , 21 , 34 , 38 …”

“…At baseline the median for FEV1 (% predicted) was 58% (range 24.36–76.2), 9 – 11 , 14 – 22 , 34 , 36 – 38 and after 3 months to 3 years of follow-up FEV1 had a median of 62% of the predicted value (range 35.6–90). 9 , 10 , 14 , 16 – 19 , 21 , 22 , 34 , 36 , 38 Three studies reported the value in liters at baseline and after treatment with a median of 2.28 L (range 1.36–5.3) pre-treatment and a median of 2.4 L (range 1.5–5.5) post-treatment. 11 , 20 , 37 …”

“…In addition, 48% were receiving or had received antifungal therapy; 106 patients (69.7%) had baseline eosinophil counts >500 cells/µL. 10 , 12 , 13 , 16 – 33 55 patients (36%) had baseline IgE serum values >1000 IU/mL. 10 – 12 , 14 , 15 , 17 – 19 , 21 , 23 – 28 , 30 – 32 , 34 , 35 …”

“…We found a total of 17 studies which included 104 patients. 9 – 11 , 14 – 22 , 34 – 38 Seven were case series, defined as ⩾three patients, nine were case reports and one was a randomized double-blind cross-over study; 89 patients (85.5%) were on long-term systemic steroids at the time of initiation of Omalizumab, 14 patients were not receiving steroids (9.2%) and in one case it was not reported. Follow-up ranged from 3 months to 3 years.…”